Bronchogen: The Definitive Guide

What is Bronchogen?

Bronchogen is a very short lab-made peptide, a chain of just four amino acids, that people take hoping to support the lungs and airways, especially for chronic bronchitis, smoking damage and slow recovery after chest infections.

It comes from a Russian research program led by Vladimir Khavinson, whose group calls these short peptides bioregulators and names each one after the organ it is meant to target: “broncho” for the airways. The patent describes the chain alanine, glutamic acid, aspartic acid and leucine, written Ala-Glu-Asp-Leu or AEDL. [1], [2]

The name now covers two different products. In Russia, Bronchogen is a dietary-supplement capsule declaring 100 mcg of a peptide complex in each capsule. Western peptide vendors sell 20 mg vials of powder for injection, usually as “research” chemicals. The capsule has a label and a few small human reports; the injectable vials have neither. Neither is an approved medicine. [3], [4], [5], [6]

Doserly

One name, two products

Capsule (Russia)

What it is: Dietary-supplement capsule, 0.2 g, declaring 100 mcg of peptide complexRoute: Oral (swallowed) with foodLabel schedule: 1–2 capsules, 1–2 times a day, for 1 month; repeat after 4–6 monthsDaily amount: 100–400 mcgHuman data: 3 small reports, no placebo

Injectable vial (Western vendors)

What it is: 20 mg vial of powder, sold as a “research” chemicalRoute: Subcutaneous injectionWebsite schedules: Most often 1–2 mg once daily for 10–20 days, 2–3 courses a yearDaily amount: 100 mcg to 5 mg across websitesHuman data: NoneCanada: Listed as an unauthorized injectable peptide (Aug 2025)

Daily amounts compared

Capsule label 0.1–0.4 mg a day; injection websites 0.1–5 mg a day (most often 1–2 mg); some English pages list 10–20 mg per capsule, at least 100× the label's 0.1 mg per capsule.

The capsule and the vial are different products with daily amounts up to 50 times apart; English pages listing 10–20 mg capsules are at least 100 times the manufacturer's figure.

Typical Bronchogen Protocols

The most common capsule protocol in the reviewed sources is 1–2 capsules, 1–2 times a day with food (100–400 mcg a day), for one month, repeated after 4–6 months. The same label wording appears on twelve pharmacy, retailer and reference pages, so it is one source copied many times rather than twelve independent opinions. [3], [8], [9], [10]

Titration Changing the amount in steps

The label does not step the amount up or down. It gives a range, and the capsule count within that range is left open. [3]

Breaks and cycles

One month on, then a repeat course after 4–6 months, so about two courses a year. A Serbian distributor instead describes a “treatment” schedule of 2 capsules twice daily for 2–4 months, repeated after 3–4 months. [3], [7]

Timing

With meals. The 2014 report gave the capsules in the morning and evening. [3], [4]

Read the units: mcg means micrograms; 1 mg equals 1,000 mcg. The capsule itself weighs 0.2 g (200 mg), but only 100 mcg of that is the declared peptide complex; the rest is filler. A newer 0.275 g capsule is also sold, and the pages we could read do not state its peptide content. [3], [9]

Each row is a complete schedule from one source, so its amount and duration belong together. Low, mid and high are alternatives, not steps to move through. These capsule schedules come from the product label and small human reports without a placebo; the cited references give the full details.

What about injectable vials?

The most common injectable pattern in the reviewed sources is 1–2 mg once a day by subcutaneous injection for 10–20 days, repeated two or three times a year. Other pages range from 100 mcg to 5 mg a day. [11], [13], [12], [14], [15], [5], [16]

The human reports all used oral capsules, and no study of Bronchogen injections in people was found in the published research or trial registries, so none of these amounts has been tested for effect or safety. [18], [4], [23], [17] The usual 1–2 mg a day is 2.5 to 20 times the capsule label's 100–400 mcg. [3]

In community education groups, educators mostly describe 0.5–2 mg a day by subcutaneous injection for 20–40 days, repeated one to four times a year, without citing a source. One educator declined to give injectable amounts at all and pointed to the capsule label instead.

Where protocols differ: products, units, course length and breaks ↓

What is Bronchogen commonly used for?

People usually look into Bronchogen because breathing has become harder work: a cough that lingers for months, a smoker's morning sputum, asthma that never quite settles, or slow recovery after bronchitis, pneumonia or COVID-19.

A Russian product directory files the capsule under acute bronchitis, chronic bronchitis and chronic obstructive pulmonary disease (COPD), and the label says it supports lung and airway function. Online, people also discuss it for asthma, quitting smoking or vaping, and lung aging. The reports below describe that interest; they do not establish that Bronchogen treats any of these conditions. [3]

Chronic bronchitis and COPD

This is where the only human research sits. The small Russian capsule reports enrolled adults with chronic bronchitis (a long-lasting cough with mucus from inflamed airways) that also had an asthma-like component, during a calm spell between flare-ups. A 2012 hospital note from Kazakhstan added five older people with COPD. [18], [4], [23]

They describe people feeling better and breathing tests improving over 20–30 days, but none had a placebo group. What the human reports can and cannot show.

Smokers and ex-smokers

Smokers and people who have recently quit are a large share of the public accounts. Russian reviewers describe less cough and sputum on the capsules; English-language posts describe easier breathing after quitting cigarettes, cannabis or vaping. Quitting itself improves cough and breathing, which makes it hard to tell what the peptide added. [24], [25], [26]

Asthma

People with asthma describe mixed experiences: some felt it helped at first, and one person said symptoms returned strongly a few months later. [27], [28] The rat and cell research does not test asthma, and the label's condition list does not include it. Bronchogen has not been shown to work as a bronchodilator (a medicine that quickly opens narrowed airways), and none of the human reports tested it for quick relief of an asthma attack. [3], [18], [4]

Recovery after chest infections and COVID-19

Many positive stories begin during recovery from bronchitis, pneumonia or long COVID. Coughs after an infection often fade on their own over weeks, so a story that starts at the worst point is likely to end better whatever was taken. The developer's group has suggested its lung peptides for further study in COVID-19, but that was a proposal in a review article, not a test. [29], [30], [31], [32]

Other uses you may come across

Some pages describe Bronchogen as “repairing” lung tissue, preventing lung aging or helping emphysema, scarring lung disease or lung cancer. Those claims go far beyond the evidence. The tissue findings behind them come from rats, cells in a dish and test-tube experiments, and none of them tested these diseases in people. [33], [1]

See the human research or explore how it might work.

Where do Bronchogen protocols differ?

The capsule label is easy to summarize. The disagreements start when a page mixes up the two products, the units or the course length. Here is what varies and why it matters.

Capsule or vial: which product is the number for?

Always check this first. Some pages put capsule and injection amounts in one table. The capsules declare 100 mcg of peptide complex each; the vials contain 20 mg (20,000 mcg) of powder. The label's highest daily amount, 400 mcg, is 2.5 to 5 times lower than the 1–2 mg a day most injection pages describe. Some people also use the name loosely for other Russian lung products that are different substances. [3], [12] Is Bronchogen the same as Chonluten?

Why do some websites give 10–20 mg capsules?

Several English pages give 10–20 mg capsules, or a “20 mg capsule”. Every manufacturer document found says 0.1 mg (100 mcg) per capsule, so those figures are at least 100 times too high; they may confuse the capsule weight or the 20 mg vial with the peptide content. Another page claims 200–400 mcg per capsule. [19], [20], [21], [16], [34], [3]

Is the number for one dose or the whole day?

Two capsules twice a day is four capsules, or 400 mcg, for the day. The label's “1–2 capsules, 1–2 times a day” therefore covers anything from 100 to 400 mcg a day. The distributor's treatment schedule of 2 capsules two or three times a day reaches 600 mcg. For injections, most pages give a single daily amount, so the dose and the daily total are the same number. [3], [7]

How many days, and how often is a course repeated?

Capsule sources agree on about a month, though some shops say 20–30 days or 1–3 months, and the Serbian distributor describes 2–4 months. Injection pages use shorter courses of 10–20 days. Community education groups describe 20–40 days. [3], [35], [7], [12]

Repeats vary from every 60–90 days to every 4–6 months, and one protocol page describes a 12-week daily course inside a five-peptide lung stack. These are different conventions, not results from a trial comparing course lengths. A 10-day, 30-day or 40-day course has not been shown to work better than another. [16], [13], [22]

Do sources start low and step up?

Almost none do. The label and most injection pages use one fixed amount for the whole course. The only step-ups found were a community education lesson (0.5 mg a day for a week, then 2 mg a day to day 40, six days on and one off) and one public account that moved from 500 mcg a day to 1 mg in a second course. [36]

How do milligrams convert to syringe units?

Injection pages often give amounts as “units” on an insulin syringe. A U-100 syringe holds 100 units per millilitre, so units measure volume, not an amount of Bronchogen. How much Bronchogen each unit holds depends on how much water was added to the vial.

For example, a 20 mg vial mixed with 2 mL of water holds 10 mg per mL, so 1 mg is 0.1 mL, or 10 units. Mixed with 3 mL, the same 1 mg is 15 units. One page lists 1 mg as 20 units because it assumes a smaller vial. Doserly's reconstitution calculator works this out for any vial and shows each step. [12], [5], [13]

What happens when you stop Bronchogen?

This has not been studied. None of the three human reports checked on people after their course ended, so nobody knows how long any change lasted or whether stopping causes withdrawal effects or a rebound. The 2007 and 2014 reports say no drug dependence was seen during treatment, but they did not look for effects after stopping. [18], [4], [23]

• Repeat courses. The capsule label suggests another course after 4–6 months. It does not explain why, and no study has measured how long any effect lasts. [3]
• Animal studies. The rat lung studies report no follow-up of the animals after treatment ended. [33], [49]
• Personal accounts. In the most detailed public account, home peak-flow readings drifted back down after the course ended, and a commenter said breathing and allergy symptoms returned whenever they paused for more than four days. A person with asthma who used Bronchogen with Chonluten said symptoms came back strongly over the following months. These are single stories with other changes going on at the same time. [36], [27] Read the accounts in full.

Do capsules and injections of Bronchogen behave the same way?

No one has measured this in people. An oral capsule has to survive stomach acid and digestive enzymes and then cross the gut wall before anything reaches the blood. A subcutaneous injection skips digestion and is absorbed from the fatty layer under the skin. Those are different starting points, so a matching amount would not mean a matching exposure, and here the amounts do not even match.

Bioavailability is how much of a dose reaches the blood in the form being measured. For Bronchogen it is unknown for every route. A 2023 computer-modelling study predicted that very short peptides like this one could fit gut transporter proteins, but a prediction is not a measurement of absorption. [39]

How long does Bronchogen last in the body?

The only data come from rats, in a Russian patent for a modified version of the peptide. It describes two separate experiments. In the first, researchers mixed a radioactively tagged form with rat blood plasma in a tube, and half of it was broken down within about 3 minutes. In the second, living rats were given a large oral dose (50 mg per kg of body weight), and the measured half-life in their blood was about 5 minutes. [40]

Two cautions apply. In the tube experiment, the tag can still be counted after the peptide has been cut up, so that number may not describe intact Bronchogen. And a rat half-life says nothing on its own about how often a person should take it or how long an effect lasts. Websites that give a human half-life in “minutes” are borrowing these rat numbers at best. [40], [16]

Does it collect in the lungs?

Some teaching materials claim that Bronchogen builds up in airway tissue. No study we found measured where Bronchogen goes in the body. The idea comes from the bioregulator theory that each short peptide acts on its own tissue, which has been tested only in cell and organ cultures. [41], [42]

How should Bronchogen be stored, and how long does it last?

It depends on the product. The capsules come with storage instructions on the label; for injectable vials, nobody has published a stability test.

• Capsules. The label says to keep them in a dry place, protected from light, at 2–25 °C (36–77 °F) and out of children's reach, with a shelf life of five years. [3], [8]
• Vial powder, before mixing. Protocol pages say to keep the freeze-dried powder frozen at −20 °C (−4 °F) or refrigerated, away from light. One claims it keeps for up to two years in a refrigerator before mixing, without citing stability data. [12], [13], [19]
• After mixing. Once the powder is mixed with liquid (reconstituted), the pages say to keep it refrigerated at 2–8 °C (36–46 °F), but their “use within” times range from 24 hours to about a month. None cites a stability test of Bronchogen. [19], [12], [11], [13], [14], [16]

We found no published stability study of Bronchogen: the capsules’ five-year shelf life is the manufacturer’s statement, and the vial times are website claims. The rat experiment in which it broke down within minutes measured blood plasma, not shelf life. [40] Health Canada warns that unauthorized injectable peptides may not have been made or stored safely, and cold storage cannot tell you what is in a vial (see product quality). [6]

What do we actually know about Bronchogen in people?

Three small human reports exist, all on the oral capsules, and two come from the developer's own institute. None used a placebo, none hid from patients or doctors who got the peptide, and none reports a clear statistical comparison of the treated and usual-care groups. ClinicalTrials.gov has no Bronchogen study, and no other registry search found one. [17]

What did the human reports find?

All three state that no side effects or complications were seen, but none says how side effects were looked for. The 2014 paper was written by Khavinson's group, whose members are the patent's inventors, and it includes no funding or conflict-of-interest statement. [18], [4], [23], [1]

Why do the 2007 and 2014 reports look so alike?

Their lung-function numbers are nearly identical even though the group sizes differ. Forced vital capacity after Bronchogen was 3,800.8 mL in the 2007 report and 3,800.7 mL in the 2014 paper. The 2007 report gives a single starting value of 2,850.6 mL, and the 2014 paper gives its usual-care group a starting value of 2,850.0 mL. Both come from the same institute. The most likely explanation is that the 2014 paper reuses the earlier data, so they should be counted as one probably overlapping dataset, not two trials. [18], [4]

The same numbers appear a third time. A report on Chonluten, a different peptide, in the manufacturer's own collection of clinical reports describes a 2005–2006 study with the same 23 treated and 19 usual-care patients, the same sex split and age range, and a lung-function table identical to the 2007 Bronchogen report, value for value. Two different products are very unlikely to produce identical results, so at least one report appears to reuse another's data, and these figures cannot be treated as evidence about Bronchogen alone. [77], [18]

What do those breathing tests measure?

Forced vital capacity (FVC) is the total amount of air you can blow out, as hard as you can, after the deepest possible breath. Vital capacity and total lung capacity, also reported, are related measures of lung volume. They matter because a test result is more objective than “I feel better”, but a single test done before and after, without a comparison group given a dummy capsule, can still shift with practice, effort and recovery from a flare-up.

The reports did not measure the outcomes that matter over years: flare-ups, hospital stays, walking distance or how fast lung function declines. A useful change is one that lasts and shows up the same way on repeated tests: fewer bad days, less breathlessness on the stairs, fewer flare-ups.

Doserly

Where the Bronchogen research comes from

Human reports (oral capsules)

3 reports. 2 in journals + 1 unpublished institute report; 2 probably share data; no placebo

Rat studies

2 publications. Plus animal examples in 2 patents (inventor data)

Cells or lung tissue in a dish

4 publications.

Test-tube DNA and protein chemistry

4 publications.

Plant studies (tobacco)

5 publications. The newest papers, 2022–2026

Computer models

2 publications.

Placebo-controlled trials

None.

Registered clinical trials

None.

Almost all from one St Petersburg research network; the rat papers came from a separate St Petersburg lung-research institute testing the network's peptide. Counts are cited reports and papers, including one unpublished institute report, not independent teams.

The human evidence is small, with no placebo; most publications are cell, test-tube, plant or computer studies.

How might Bronchogen work?

The developers' idea is that short peptides act as tissue-specific signals, switching genes on or off in airway-lining cells. The experiments below test pieces of that idea. They are preclinical (in cells, animals and test tubes), and almost all come from one research network.

What happens in airway cells grown in a dish?

In cell studies using human embryonic bronchial cells (airway-lining cells grown in a dish, not people), Bronchogen changed the activity of genes and proteins linked to cell renewal and to the specialized cells of the airway lining, including mucus-making cells. Some effects were larger in older, repeatedly grown cultures, which the authors treat as a model of aging. Not every marker changed. [43], [4], [44], [45]

A related experiment kept small pieces of lung from young and old rats alive in a dish; tiny amounts of Bronchogen increased their growth. A dish is a long way from a working lung. [41]

Does it really bind DNA?

In test-tube experiments with DNA extracted from animals, the peptide attached to DNA and made it slightly more resistant to heat, raising its melting point by 3.1 °C. It also bound certain short DNA pieces more than others and loosened packed DNA from rat liver cells. The group proposes that this is how it switches genes, but these experiments did not show it happening inside a living lung. [46], [47], [48]

What did the rat lung studies find?

In rats that breathed nitrogen dioxide (an air pollutant) for 60 days to cause COPD-like damage, a one-month course of Bronchogen was followed by less inflammation, fewer abnormal mucus cells, more healthy hair-like (ciliated) cells and more of a protective antibody in the airways. These studies came from a St Petersburg lung-research institute outside the developer's own, although they tested the developer's peptide. [33], [49]

The patent adds rat experiments in lung infection, lung scarring and oxygen damage. In the scarring model, the peptide “did not utterly prevent” scar tissue but the changes were less severe. These results are the inventors' own data and were not independently published. [1]

Which sequence is it: AEDL or ADEL?

The patent and the PubChem chemical database give Ala-Glu-Asp-Leu (AEDL). Three papers from the same network print Ala-Asp-Glu-Leu (ADEL), which is a different molecule with the same formula and weight. A 2014 Russian paper reports the same airway-cell experiments with AEDL, which suggests a misprint, but that has not been confirmed. The capsule label lists the four amino acids without giving their order. [1], [2], [43], [46], [4], [3]

Explore every Bronchogen experiment in the research library.

What are the risks and unanswered questions?

Is Bronchogen safe?

Its safety in people has not been established. The capsule reports and the label say no side effects were seen, but no study described how side effects were collected, the reports were small and short, and we found no human data at all for injected Bronchogen. [18], [4], [23], [3]

The patent's animal tests found no obvious toxicity in mice, rats and guinea pigs, including daily injections for up to six months at amounts far above the rat treatment dose. The same tests did record a rise in white blood cells (leukocytes) in guinea pigs at six months. That is an animal finding by the inventors, and its meaning is unclear. [1]

What problems have actually been reported?

Very few, and none formally. In one public thread, a person using injected Bronchogen reported immediate flushing and a heart rate of 106 beats a minute after injections. Community education groups reviewed for this guide contained no reported side effects, but the reports were few and several members who started it never posted an outcome, so silence is not evidence of safety. [36] No published case report of harm from Bronchogen was found. Health Canada's warning about one company's unauthorized injectable peptides names Bronchogen but does not describe any harm from it. [6]

Could product quality change the risk?

Yes. The vials are sold as unregulated “research” chemicals, and no manufacturer has published the peptide sequence, purity, sterility or testing of an injectable Bronchogen product that we could find. Health Canada says the injectable peptides it seized, Bronchogen among them, “have not been assessed for safety, efficacy, and quality”. Injecting any unapproved product adds risks of infection, contamination and allergic reaction. [6]

Is Bronchogen legal? Is it FDA-approved?

Checked September 23, 2026. Rules differ by country and change quickly. A “research use only” label does not make a product legal to sell or safe to use.

United States. Bronchogen is not an FDA-approved medicine: a search of FDA's approved-drug database found no entry. [76] It is not on FDA's list of compounding ingredients that may pose significant safety risks (page current as of April 22, 2026), but absence from that list is not an FDA safety judgment. [50]

Canada. Health Canada's August 1, 2025 advisory lists Bronchogen among “unauthorized injectable peptide drugs” seized from and sold by one Canadian company. Injectable peptides are regulated as prescription drugs in Canada, and selling unauthorized drugs is illegal. The advisory concerns injectable products; it does not assess the Russian capsules. [6]

Australia. Bronchogen is not approved in Australia. Searches of the Australian Register of Therapeutic Goods found no entry, and it is not named in the June 2026 Poisons Standard. The TGA's May 2026 warning on imported peptides warns of significant risks to patient safety and says personal importation is permitted only if products are clearly and accurately labelled. Labelling is one condition, so a well-labelled vial is not automatically legal to import. [51], [52], [53]

United Kingdom. A search of UK government sites, which include the medicines regulator (MHRA), found no record for Bronchogen. [54]

Russia. The capsules are sold as a dietary supplement (a biologically active food additive), not as a registered medicine. [3]

Is Bronchogen banned in sport? Does it show up on a drug test?

Bronchogen is not named on the World Anti-Doping Agency's 2026 list or on the 2027 list that takes effect on January 1, 2027. Category S0 bans at all times any substance “with no current approval by any governmental regulatory health authority for human therapeutic use”, and the 2027 list adds “peptides” to its examples. WADA has not ruled on Bronchogen specifically, and a Russian supplement registration is not a medicine approval, so tested athletes should assume S0 can apply. [55], [56]

No published anti-doping test for Bronchogen was found, and how long it could be detected is unknown.

Does Bronchogen cause cancer?

Nobody knows. There are no long-term human data and no standard long-term animal cancer studies. In airway cells, Bronchogen increased markers of cell division, most in “old” cultures; that neither shows a cancer risk nor rules one out. Claims that it treats lung cancer have no evidence behind them. [43], [1]

Who should be especially cautious?

These groups have no safety data in people. That is a reason for caution, not proof of harm.

• Pregnancy and breastfeeding. The capsule label lists both as reasons not to use it. [3]
• Children and teenagers. No study included anyone under 34, and this guide is written for adults. One community discussion involved a parent considering it for a child with severe asthma; there is no evidence for that use.
• Serious lung disease. People with COPD, emphysema, lung scarring, lung infections or suspected lung cancer need medical care. Bronchogen has been tried in only five people with COPD and not at all in the others, and community suggestions to use it for them carry no evidence. [23]
• A history of cancer. Because of the unanswered growth-signal questions above.
• Competitive athletes. See the anti-doping section above. [56]
• People taking other medicines. Interactions have not been studied; see the next question.

Has Bronchogen been tested alongside other medicines?

Not in any way that answers the question. In the human reports, everyone also received usual care for bronchitis, but the reports do not describe any interactions. Nothing is known about combining Bronchogen with inhalers, steroids, antibiotics, blood thinners or other peptides. Bring a complete list of everything you take to a pharmacist or doctor. [4], [18]

It is not a substitute for any of them: an inhaler, an antibiotic for pneumonia or oxygen treats a problem now, and Bronchogen has no evidence of doing so.

What should be monitored while using Bronchogen?

No regulator has written a monitoring plan for Bronchogen. The capsule label only advises talking to a doctor before use, and the injectable vials are sold for laboratory research, with no approved label or monitoring plan. What exists is a record of what the small human reports and the patent's animal safety tests checked. It can help you prepare questions for a clinician; it is not a personal testing plan. [3]

What did the human reports check?

• Breathing tests. All three repeated spirometry, a breathing test that measures how much air you can blow out and how fast. [18], [4], [23]
• Symptoms and sputum. The 2007 and 2014 reports recorded complaints such as cough, sputum (mucus coughed up) and breathlessness, and examined the sputum under a microscope. The 2007 report also listened to the chest. [18], [4]
• Blood, urine and X-rays. The 2007 report says it ran routine blood and urine tests, blood chemistry and chest X-rays, but it published no results for them. The 2012 note checked laboratory tests, heart tracings (ECG) and blood pressure after two weeks and reported only a pooled improvement across two peptides. [18], [23]
• Side effects. All three say none were seen, without saying how they were looked for. [18], [4], [23]

What did the animal safety tests check?

The patent's toxicity tests gave mice a single injection, rats daily injections for 90 days and guinea pigs daily injections for six months. The inventors examined the animals' general health, blood counts, blood chemistry, heart, lung, liver and kidney function, and their internal organs under a microscope. The only change they reported was a rise in white blood cells (leukocytes) in guinea pigs at six months. [1]

Which measures matter, and why?

Health Canada advises anyone who has used an unauthorized injectable peptide and has health concerns to talk to a doctor, nurse practitioner or pharmacist, and to report side effects. [6]

What do people in public communities report?

Public accounts split along the two products. English-language Reddit users mostly inject vials, often alongside other peptides. Russian-language reviewers mostly take the capsules. Across both, the stories are usually short, positive and hard to interpret, with a few detailed exceptions worth reading closely. [36], [57]

What do the positive reports look like?

The capsule reviews describe less cough and sputum and easier breathing. One reviewer took 1 capsule twice daily for 18 days during recovery from a bronchitis flare, noticed nothing in the first week, then coughed less and could manage without their steroid inhaler. Another took two monthly courses after two bouts of pneumonia, antibiotics and physiotherapy, and said the cough, breathlessness and weakness were gone by the end of the first month. [57], [29]

Injection users describe deeper breaths and better “lung function”. One took 1 mg a day of Bronchogen together with 1 mg a day of Chonluten while recovering from long COVID. Another said 500 mcg a day for a month “made such a difference” without saying what changed. [31], [58]

Most positive stories begin while an infection is clearing or soon after quitting smoking, and many include Chonluten, other peptides or new inhalers.

How long did those changes last?

The most detailed public account used a home spirometer (a breathing-test device). Over a 40-day course of 500 mcg a day by subcutaneous injection, peak flow (how fast you can blow air out) rose from 490 to 574 litres a minute. A second course at 1 mg, six days on and one off, followed. The readings drifted back down after stopping. The same person was also taking BPC-157 and TB-500, powerlifting, using a rescue inhaler as needed and getting ill at times. [36]

A commenter on that thread said symptoms came back whenever they paused for more than four days. A person with asthma said Bronchogen and Chonluten seemed to help at first, then symptoms returned strongly over the following months. [36], [27]

Does everyone notice a difference?

No. Several capsule reviewers wrote that they noticed nothing, or that the effect was “very weak”. One injection user found the results inconclusive after a week and later traced the problem to their ribs, not their lungs. [59], [60], [61], [62]

The most careful self-test, by a person investigating mild emphysema, ran 1 mg a day by subcutaneous injection for 20 days with home spirometry and a CT scan. The person was also taking N-acetylcysteine (a mucus-thinning supplement) and compared home readings with a clinic baseline. Their conclusion: “it is not possible to say if the treatment had any effects.” Weeks later they described “a small improvement”. [63], [64]

What about unwanted effects?

Only one public account described a reaction: immediate flushing and a faster heart rate after injections. One self-report cannot show how common that is or what caused it. See reported problems. [36]

What do community education groups teach?

Educators in community education groups describe Bronchogen as a slow-acting peptide meant to restore the airway lining, not a bronchodilator, and often pair it with Chonluten or VIP (vasoactive intestinal peptide). Some treat Bronchogen, Chonluten and Bronchalamin as interchangeable lung options, although they are different substances.

Members' experiences follow the public pattern: a handful of positive reports, mostly during recovery from an illness or after quitting smoking and usually with other peptides, a couple of unsure results, and several people who started and never reported back. Some advice went beyond any evidence, such as calling bioregulators harmless for someone with a cancer history or suggesting Bronchogen for serious lung infections and lung cancer.

How can you judge a breathing story?

Ask: Was an infection already clearing? Capsule or vial, and how much? What else changed: quitting smoking, inhalers, steroids, antibiotics, other peptides? Was anything measured the same way before and after? What happened months later?

These selected discussions are not a survey of all users, a response rate or a substitute for controlled studies. Public posts include a vendor-run forum and review sites that may reward reviewers, so some accounts may be promotional. [65], [26]

How does Bronchogen compare with Cardiogen, Epitalon and VIP?

Bronchogen is often discussed alongside other short peptides from the same Russian program and alongside VIP, which some people pair with it for the lungs. The table compares what each one is and how much human evidence exists.

The real differences are in how much has been tested, not in proven results. Bronchogen, Cardiogen and Epitalon differ by only one or two amino acids. Bronchogen and Cardiogen have only a few small Russian capsule reports without a placebo, and Epitalon's three small human studies include one placebo-controlled study. VIP is a natural, longer peptide that has been tested in larger trials, including one that found no clear benefit in severe COVID-19. No human study has compared any of them with Bronchogen. Chonluten, a three-amino-acid peptide (Glu-Asp-Gly) that some people take with Bronchogen, has no Doserly guide yet; the only human report on it we found repeats the Bronchogen report's numbers (see above). [66], [31], [27], [77]

Common questions about Bronchogen

Is Bronchogen a pill or an injection?

Both are sold, and they are different products. The original Russian Bronchogen is a capsule taken with food, declaring 100 mcg of peptide complex. Western vendors sell 20 mg vials of powder for injection. Only the capsule has a product label and human reports; we found no study of the injection. [3], [4], [17] See the two protocol tables.

How long does Bronchogen take to work?

There is no reliable answer. The human reports measured results after 20–30 days. Public accounts range from “day one” to about three weeks, and some people noticed nothing at all. Early changes during recovery from an infection are especially hard to credit to the peptide, since coughs often ease on their own. The educators who promote it describe it as slow-acting rather than immediate. [4], [65], [57], [59] See what people reported over time.

Is Bronchogen the same as Chonluten or Bronchalamin?

No. Chonluten is a different, three-amino-acid peptide (Glu-Asp-Gly, or EDG) from the same Russian program, also promoted for the airways. Bronchalamin is a powder made from the airway lining of cattle and pigs, sold as tablets, not a single lab-made peptide. People often take Bronchogen with Chonluten, which is one reason their stories cannot show what Bronchogen did on its own. Research on Chonluten or Bronchalamin cannot be counted as research on Bronchogen. [32], [66], [67], [68]

Is Bronchogen the same as AEDG or Epitalon?

No. AEDG (Ala-Glu-Asp-Gly) is Epitalon, a different four-amino-acid peptide from the same program, even though at least one website lists AEDG as another name for Bronchogen. One letter differs, and so does the molecule. Bronchogen's patent sequence is AEDL. [32], [38], [1] Read the Doserly Epitalon guide.

Can Bronchogen replace an inhaler or COPD treatment?

The reviewed evidence gives no reason to think so. In every human report, Bronchogen was added to usual treatment, not used instead of it, and it has not been shown to work as a bronchodilator. Stopping prescribed inhalers, antibiotics or oxygen to try it could be dangerous. [18], [4] See interactions and cautions.

Is it legal to buy Bronchogen?

It depends on the country and the product. The capsules are sold as a supplement in Russia. Injectable Bronchogen is not approved in the United States, and Health Canada lists it among unauthorized injectable peptides. A “research use only” label does not make a product legal or safe. See the dated legal-status summary. [3], [50], [6]

Is a longer course more likely to work?

Nothing shows that. Courses range from 10 days to 4 months across the sources, and no one has compared them. Longer use also raises safety questions that short, small reports cannot answer. [12], [7], [4]

Glossary

Plain explanations of the route, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Amino acid

A small chemical building block. Chains of amino acids make up peptides and proteins.

Animal study

Research in animals such as rats or mice. It shows what a substance does in a living body, but results in people can differ.

Bioavailability

How much of a dose reaches the bloodstream in a usable form. It depends heavily on the route. For Bronchogen it has not been measured by any route.

Bioregulator

The name a Russian research group uses for very short peptides it believes act on particular tissues. It is a marketing and research label, not a regulatory category.

Bronchodilator

A medicine that relaxes the muscles around the airways so they open quickly, such as a rescue inhaler. Bronchogen has not been shown to work as one.

Cell study (in vitro)

Research on cells grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

COPD

Chronic obstructive pulmonary disease: long-term lung damage, usually from smoking, that narrows the airways and makes breathing out harder. It includes chronic bronchitis and emphysema.

Course and cycle

A course is the period of repeated use, such as one month. A cycle is a course plus a planned break before any further use.

Daily total

All the amounts given in one day, added together. For example, 2 capsules of 100 mcg twice daily is a 400 mcg daily total.

Dietary supplement

A product sold as a food additive rather than a medicine. In Russia these are registered with lighter requirements than medicines and do not have to prove they work.

Dose (amount each time)

The amount given on one occasion. A protocol lists both the dose and how often it is given.

ECG (electrocardiogram)

A quick, painless recording of the heart's electrical activity through stickers placed on the skin. A 2012 report that included Bronchogen checked it during treatment.

Forced vital capacity (FVC)

The total amount of air a person can blow out as hard as possible after the deepest possible breath. It is a standard breathing test.

Half-life

The time it takes for the measured level of a substance in the blood to fall by half. It is not the same as how long an effect lasts.

Investigational

Still being studied and not approved by a regulator, such as the FDA, to treat any condition.

mcg and mg

Micrograms and milligrams. 1 mg equals 1,000 mcg. Bronchogen capsules declare 100 mcg each; injection amounts are usually written in mg.

Oral

Taken by mouth, as a capsule, tablet or liquid.

Peptide

A short chain of amino acids. Bronchogen is a chain of four, called a tetrapeptide.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance. For Bronchogen, only rat data exist.

Placebo

A dummy treatment with no active ingredient, used as a comparison in studies.

Preclinical research

Studies done before research in people: cell studies, test-tube experiments and animal studies.

Reconstitution

Mixing a freeze-dried powder with a sterile liquid so it becomes a solution. How long mixed Bronchogen stays usable has not been tested.

Research use only

A label on products sold for laboratory research. It does not mean a product is approved, tested for human use or legal to sell as a medicine.

Spirometry

A breathing test in which you blow as hard and fast as you can into a device that measures how much air comes out and how quickly. Forced vital capacity is one of its results.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. This is the route most injectable Bronchogen descriptions use.

Syringe units

Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL. The amount of drug per unit depends on the vial's concentration.

Titration

Adjusting a dose in steps, usually starting lower and increasing if needed.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport.

Explore more of the research

Go deeper into the experiments behind the claims.

Across this guide, the citations include 19 original scientific papers on Bronchogen: two small human reports in journals and 17 preclinical papers on cells, test-tube chemistry, rats, plants and computer models. Two patents and an unpublished institute report are counted separately, and the comparison section adds two papers on VIP. The library below explores 18 of the Bronchogen papers and both patents, grouped by question. Paper counts are not counts of independent research teams: almost all come from one research network, and some may share data.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: published scientific studies, patents, trial-registry searches, regulatory documents, product labels and published protocol descriptions. We also reviewed public online forums and review sites, and community education groups, where people describe their own experiences with Bronchogen.

The guide cites 87 sources, including 21 original scientific papers. Each type of source answers a different question. Studies show what researchers measured. Protocol descriptions show how Bronchogen is typically used. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources